News & Events
Chapel-en-le-Frith, UK, 21st February 2006
Peakdale Extends its Range of Medicinal Chemistry Services
Peakdale Molecular Ltd announces the extension of its first-class range of Medicinal Chemistry Services to further support its customers' drug discovery programmes. The services enable the Company to provide compounds with a superior starting point for hit discovery, resulting in significant savings for subsequent optimisation.
The Company has added to its medicinal chemistry expertise and developed computer-aided drug design (CADD) tools that build on its core strength of highly innovative synthetic chemistry. Peakdale has a proven track record of delivering superior compounds that add-value to customers' drug discovery programmes with a rapid turnaround and has a reputation for maintaining the highest standards of confidentiality and helping customers to establish ownership of intellectual property.
Peakdale's Medicinal Chemistry Services are designed to complement its customers' drug discovery initiatives through hit-to-lead and lead optimisation projects, patent protection projects, back-up chemotypes and fast follower candidate programmes. They also include the synthesis of chemogenetic arrays on an exclusive basis utilising Peakdale's unique, privileged scaffolds. The services are underpinned by Peakdale's strength in CADD, used to simulate drug-receptor interactions. The Company's expertise in this specialist discipline enables its scientists to frontload compounds with beneficial ADMET properties and to construct 3D-QSAR models to identify favourable regions of chemical space.
About Peakdale Molecular Ltd:
Peakdale Molecular was founded in 1992. Today, the
Company's
customers include 18 of the top 20 global pharmaceutical
companies and an increasing number of biotechnology companies.
Its teams of chemists combine experience in pharmaceutical
R&D and process development, medicinal chemistry, parallel
synthesis and fine chemicals to deliver unique chemistry
solutions to a range of drug discovery challenges. Application
of less commonly used chemistry, including high temperature/pressure
reactions, proprietary heterocyclic chemistry and nucleoside
synthesis, enables Peakdale's chemists to generate unique
compounds for drug discovery. Peakdale operates in several
distinct markets providing novel screening compounds, targeted
screening libraries, catalogue intermediates, custom synthesis
and contract research. Further information about the Company
can be obtained at www.peakdale.co.uk
For more information please contact:
At
the Company
Glenn Killingworth, Business Development Manager
+44 (0)1298 816700
glenn.killingworth@peakdale.co.uk
Media Enquiries:
Ben Routley, Northbank Communications
+44 (0)1260 296500
b.routley@northbankcommunications.com